Send to

Choose Destination
Kidney Dis (Basel). 2017 Jul;3(1):8-14. doi: 10.1159/000477244. Epub 2017 Jun 16.

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.

Hocher B1,2,3,4, Pasch A5.

Author information

Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany.
IFLb, Institut für Labormedizin Berlin, Berlin, Germany.
Department of Embryology, Medical School of Jinan University, Guangzhou, China.
Department of Nephrology, Guangzhou Overseas Chinese Hospital, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Department of Clinical Research, University Hospital Bern, University of Bern, Bern, Switzerland.



Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients.


In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified.


There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome.


Biomarker; Calcification propensity; Chronic kidney disease-mineral and bone disorder; Morbidity; Mortality; Nonoxidized parathyroid hormone; T50 test

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center